Pharmacokinetics of the cyclosporine-ketoconazole interaction in dogs.
Numerous clinical reports have documented an increase in trough blood concentrations of cyclosporine in transplant recipients treated concomitantly with ketoconazole. The objective of this study was to elucidate the mechanism(s) underlying the cyclosporine-ketoconazole interaction using a choledochoureterostomy dog model. Five male beagle dogs received a 4 mg/kg, i.v. bolus dose of cyclosporine either alone or on day seven of a 10-day, 13 mg/kg/day, oral dosing regimen of ketoconazole. Blood samples were collected prior to and at predetermined times for 60 hrs after the cyclosporine dose, while the bile/urine mixture was collected quantitatively for 96 hours after the cyclosporine dose. Ketoconazole decreased the systemic clearance of cyclosporine from 7.0 ml/min/kg to 2.5 ml/min/kg. The terminal disposition rate constant was also decreased significantly from 0.0794 to 0.0354 hrs-1. Ketoconazole caused no significant changes in cyclosporine steady state volume of distribution, or plasma unbound fraction. Ketoconazole did not significantly alter the excretion of cyclosporine and various cyclosporine metabolites in the bile/urine mixture. Inhibition of hepatic drug metabolizing enzymes appears to be the primary reason for the ketoconazole induced elevation in cyclosporine concentration.
D'mello
A
A
School of Pharmacy, University of Pittsburgh, Pa 15261.
Venkataramanan
R
R
Satake
M
M
Todo
S
S
Takaya
S
S
Ptachcinski
R J
RJ
Burckart
G J
GJ
Starzl
T E
TE
D000818:Animals; D001646:Bile / Q000378:metabolism; D001798:Blood Proteins / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D003524:Cyclosporins / Q000493:pharmacokinetics* / Q000494:pharmacology; D004285:Dogs; D004347:Drug Interactions; D006207:Half-Life; D007275:Injections, Intravenous; D007654:Ketoconazole / Q000493:pharmacokinetics* / Q000494:pharmacology; D008099:Liver / Q000378:metabolism; D008297:Male
D001798:Blood Proteins; D003524:Cyclosporins; D007654:Ketoconazole